In a GBM mouse model, treatment with anti-TIGIT/anti-PD-1 resulted in increased survival of the mice, reduced tumor volume, and increased immune infiltration in tumor lesions compared to single ICBs or isotype treatments [78]. Here, TIGIT is linked to neoplasm.